XML 72 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
FAIR VALUE DISCLOSURES (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
May 31, 2018
Apr. 30, 2018
Feb. 28, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets       $ 5,169 $ 50,956  
Long-term Debt, Total       134,100    
Finite-Lived Intangible Assets, Gross       288,215   $ 284,716
Inventory, Finished Goods, Gross       10,317 [1]   13,901 [2]
InventoryRawMaterials       26,653 [1]   22,139
Derivative Asset, Notional Amount       $ 72,200    
Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate       15.00%    
Inderal XL [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Finite-Lived Intangible Assets, Gross     $ 15,100      
Finite-Lived Intangible Asset, Useful Life     10 years      
Acquisition Costs Capitalized     $ 40      
Inventory, Finished Goods, Gross     5,000      
Asset Acquisition Purchase Price     $ 20,200      
Inderal XL [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate     10.00%      
InnoPran XL [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Finite-Lived Intangible Assets, Gross     $ 19,000      
Finite-Lived Intangible Asset, Useful Life     10 years      
Acquisition Costs Capitalized     $ 100      
Inventory, Finished Goods, Gross     11,600      
Asset Acquisition Purchase Price     $ 30,600      
InnoPran XL [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate     10.00%      
InnoPran XL [Member] | Cash [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets     $ 600      
InnoPran XL [Member] | Line of Credit [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets     $ 30,000      
Fair Value, Inputs, Level 1 [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Notes Payable, Fair Value Disclosure       $ 146,800    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Interest Rate Derivative Assets, at Fair Value       $ 700    
Equipment [Member] | Impax Laboratories, Inc. [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Finite-Lived Intangible Assets, Gross $ 58          
Finite-Lived Intangible Asset, Useful Life 5 years          
Teva Pharmaceuticals [Member] | Milestone One [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Contingent Liability Not Recognized $ 25,000          
Teva Pharmaceuticals [Member] | Milestone Two [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Contingent Liability Not Recognized 15,000          
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets 2,300          
Finite-Lived Intangible Assets, Gross $ 1,000          
Finite-Lived Intangible Asset, Useful Life 10 years          
Acquisition Costs Capitalized $ 100          
Contingent Consideration In An Asset Purchase $ 10,000          
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate 15.00%          
Abbreviated New Drug Applications [Member] | Impax Laboratories, Inc. [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate 10.00%          
Abbreviated New Drug Applications [Member] | IDT Australia, Limited [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate   15.00%        
Abbreviated New Drug Applications [Member] | IDT Australia, Limited [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate   10.00%        
Acquired New Drug Applications [Member] | IDT Australia, Limited [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets   $ 2,700        
Finite-Lived Intangible Assets, Gross   $ 2,500        
Finite-Lived Intangible Asset, Useful Life   10 years        
Acquisition Costs Capitalized   $ 18        
InventoryRawMaterials   $ 200        
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Finite-Lived Intangible Assets, Gross $ 1,300          
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate 75.00%          
AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Payments to Acquire Intangible Assets           46,500
Finite-Lived Intangible Assets, Gross           $ 46,700
Finite-Lived Intangible Asset, Useful Life           10 years
Acquisition Costs Capitalized           $ 200
Accumulated Capitalized Interest Costs           200
Contingent Consideration In An Asset Purchase           $ 3,000
AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member] | Measurement Input, Discount Rate [Member]            
Fair Value Inputs, Assets, Quantitative Information            
Fair Value Input Discount Rate           10.00%
[1] Includes inventory acquired in acquisition of WellSpring (Note 3).
[2] Includes finished goods acquired in asset purchases (Note 13).